Podcasts about clin

Retrouvez Eric Célis & Michel Turco pour #TalkbackGP !Votre rendez-vous #motogp

durée : 00:47:19 - Les Nuits de France Culture - par : Albane Penaranda - Au 19e siècle, la médiumnité devient en France un espace où des femmes longtemps marginalisées accèdent à la parole, au savoir et à une certaine forme de pouvoir. La chercheuse Nicole Edelman retrace cette histoire méconnue, à la marge des croyances, de la science et de l'émancipation féminine. - réalisation : Mathias Le Gargasson, Antoine Dhulster, Rafik Zénine, Vincent Abouchar, Emily Vallat, Hassane M'Béchour, INA Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

A 10h, ce mardi 9 juin 2026, les GG : Zohra Bitan, fonctionnaire, Didier Giraud, éleveur de bovins, et Joëlle Dago-Serry, coach de vie, débattent de : "Déclin démographique, la retraite à 68 ans inéluctable ?"

durée : 00:20:04 - Le journal de 18h00 - La population française pourrait baisser dans les prochaines décennies, alerte l'Insee dans ses dernières projections. En 2070, les plus de 65 ans pourraient être deux fois plus nombreux que les jeunes de moins de 20 ans. Conséquence du recul de la natalité. - réalisation : La Rédaction de France Culture, Stanislas Vasak, Brice Garcia Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:20:04 - Les journaux de France Culture - La population française pourrait baisser dans les prochaines décennies, alerte l'Insee dans ses dernières projections. En 2070, les plus de 65 ans pourraient être deux fois plus nombreux que les jeunes de moins de 20 ans. Conséquence du recul de la natalité. - réalisation : La Rédaction de France Culture, Stanislas Vasak, Brice Garcia Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Cette semaine au Libre Podcast, Francis Denis reçoit François Fournier pour une grande revue de l'année politique et sociale au Québec et au Canada. Ensemble, ils dressent un bilan de l'état des libertés, des débats qui ont marqué l'actualité et des défis qui attendent les défenseurs de la liberté d'expression et des droits individuels dans les années à venir. En seconde partie, Virginie Dostie-Toupin analyse les premiers mois du gouvernement de Mark Carney et revient sur ce qu'elle considère comme un bilan décevant. La discussion aborde également les symptômes du déclassement économique, politique et culturel du Canada, ainsi que les conséquences de cette trajectoire pour l'avenir du pays. ➡️ SITE WEB : https://libre-media.com/ MERCI DE SOUTENIR LA PRESSE INDÉPENDANTE Pour s'abonner : https://libre-media.com/abonnement SUIVEZ-NOUS ! Twitter : / libremediaqc Facebook : / libremediaqc Instagram : / libre.media Copyright © 2026 Libre Média – Tous droits réservés  

Retrouvez Eric Célis & Michel Turco pour #TalkbackGP !Votre rendez-vous #motogp

Langue française : la baisse du niveau chez les jeunes inquiète le corps enseignant face au déclin de la lecture by TOPFM MAURITIUS

Le week-end dernier, des frappes massives sur Kiev. En début de semaine, un appel aux ressortissants étrangers à quitter la capitale ukrainienne. Moscou fait pression, mais n'est-ce pas une tentative de dissuasion ? L'économie russe souffre de plus en plus, tout comme la population à l'épreuve d'une guerre qui met à mal leur quotidien. Quels éléments permettraient d'affirmer que le président russe se trouve dans une position défavorable ? Quelles perspectives possibles pour la Russie dans le contexte international actuel, alors que les tentatives pour mettre fin au conflit ont échoué ? Pour en débattre - Francoise Daucé, directrice d'études à l'EHESS (L'École des Hautes études en Sciences sociales). Elle a co-dirigé Genèse d'un autoritarisme numérique. Répression et résistance sur Internet en Russie, édition des Mines. Autrice du livre Être opposant dans la Russie de Vladimir Poutine. Éditions Le Bord de l'eau - Jean De Gliniasty, ancien ambassadeur de France en Russie, directeur de recherche à l'Institut de relations Internationales et stratégiques (IRIS) - Nicolas Tenzer, spécialiste des questions internationales sur Tenzer Strategics. Auteur des livres « Notre guerre » et « Fin de la politique des grandes puissances », éditions de L'Observatoire. 

Le week-end dernier, des frappes massives sur Kiev. En début de semaine, un appel aux ressortissants étrangers à quitter la capitale ukrainienne. Moscou fait pression, mais n'est-ce pas une tentative de dissuasion ? L'économie russe souffre de plus en plus, tout comme la population à l'épreuve d'une guerre qui met à mal leur quotidien. Quels éléments permettraient d'affirmer que le président russe se trouve dans une position défavorable ? Quelles perspectives possibles pour la Russie dans le contexte international actuel, alors que les tentatives pour mettre fin au conflit ont échoué ? Pour en débattre - Francoise Daucé, directrice d'études à l'EHESS (L'École des Hautes études en Sciences sociales). Elle a co-dirigé Genèse d'un autoritarisme numérique. Répression et résistance sur Internet en Russie, édition des Mines. Autrice du livre Être opposant dans la Russie de Vladimir Poutine. Éditions Le Bord de l'eau - Jean De Gliniasty, ancien ambassadeur de France en Russie, directeur de recherche à l'Institut de relations Internationales et stratégiques (IRIS) - Nicolas Tenzer, spécialiste des questions internationales sur Tenzer Strategics. Auteur des livres « Notre guerre » et « Fin de la politique des grandes puissances », éditions de L'Observatoire. 

Un projet ambitieux décliné en deux volets, dont la deuxième partie est sortie le 22 mai 2026, avant la première, un choix assumé et pensé comme un clin d'œil à Star Wars et à George Lucas, qui avaient lancé leur saga par les épisodes 4, 5 et 6.

Dr. Deb Muth 00:04What if the future of healing isn’t about replacing cells, but about teaching your body how to heal itself again? We keep hearing the words stem cells and exoomes thrown around like they’re interchangeable, but they’re not. One is regulated, controversial, and often misunderstood. The other is rapidly emerging as one of the most exciting communication systems in human biology. Dr. Deb Muth 00:33And here’s the real question no one’s asking. Are we actually regenerating tissue or are we just stimulating the body to remember how it used to heal? Tired of being told your labs are normal, but you still feel terrible? At Serenity Healthcare Center, we don’t chase symptoms. We find the root cause. hormones, gut health, autoimmune conditions, chronic fatigue, brain fog. Dr. Deb Muth 01:02We use cuttingedge functional and regenerative medicine to get you real answers and a real path forward. This isn’t your average doctor’s office. This is medicine the way it was meant to be practiced. You deserve to feel like yourself again. Visit serenityhealthcarecenter.com to book your appointment today. Let us help you heal from the inside out. Dr. Deb Muth 01:28Welcome back to Let’s Talk Wellness Now. I’m Dr. Deb, your host. And if you’ve been following regenerative medicine, you’ve probably noticed the confusion. Patients are asking me every week, are exoomes stem cells? Are stem cells legal in the United States? I heard the FDA is shutting down all these clinics. Can I even get this therapy? Do I have to leave the country for treatment? Today, we’re cutting through the noise. This episode is not hype. Dr. Deb Muth 01:54It’s not sales. It’s education so you can understand the science, the regulatory reality, and the clinical difference between stem cell therapy and exoome therapy. And here’s what I want you to know right up front. Yes, these therapies are being used in the United States every single day. Yes, they’re being offered by highly trained physicians in integrative and regenerative medicine clinics across the country. Dr. Deb Muth 02:22Some are being used in FDA registered clinical trials. Some are being used in observational studies and some are being used in clinical practice under physician discretion. The landscape is nuanced and you deserve to understand it. So, grab your cup of coffee or tea and settle in for a deep dive into the most understood therapies in regenerative medicine. Dr. Deb Muth 02:43what they actually are, how they work, the regulatory landscape, and how they might support your body’s natural healing capacity. Let’s talk wellness now. So, let me start by asking you something. When you hear the word stem cell, what do you picture? Most people imagine damaged tissues magically regenerating or a torn meniscus growing back, cartilage reforming it into an arthritic joint or damaged brain tissue being replaced with healthy new beautiful cells. It’s a beautiful vision. Dr. Deb Muth 03:15And while it’s not quite that simple, the reality is actually more sophisticated and honestly more beautiful. Stem cells are powerful and they absolutely work, but the way they work and the mechanism by which they support healing is far more elegant and more so than most people really understand. And if you’re going to invest in regenerative therapy, you deserve to understand what you’re actually receiving. Dr. Deb Muth 03:44So, let’s start at the beginning. What are stem cells? At their core, stem cells are undifferentiated cells. That means they haven’t yet decided what they want to be when they grow up. Unlike a heart cell or a skin cell or a bone cell which have already committed to a specific function, stem cells exist in this beautiful state of potential. Dr. Deb Muth 04:05They have two remarkable abilities. First, they can self-renew. They can make copies of themselves, maintaining a reserve of these powerful cells throughout your lifetime. Second, they can differentiate under the right conditions. They can transform into specialized cell types. Bone cells, cartilage cells, nerve cells, muscle cells, even blood cells. Dr. Deb Muth 04:27This is why they’ve captured the imagination of the medical world. The potential is extraordinary. Now, there are several types of stem cells and understanding the differences matters tremendously for both understanding how they work and understanding how they’re regulated. Adult mezzenymal stem cells. We call these MSC’s are the most commonly used regenerative medicine. Dr. Deb Muth 04:54These come from bone marrow, atapost tissue, that’s fat, and other adult sources. They’re what we can call multi-potent, meaning they can become several types of cells, but not every type. A bone marrow stem cell isn’t going to become a brain cell, for instance. It has potential but it’s directed potential. Dr. Deb Muth 05:19Then we have perinatal stem cells. These come from umbilical cord blood cord tissue or something called Wharton’s jelly which is the gelatinous substance inside the umbilical cord. These cells are younger, more potent, and research by Weiss and colleagues published in stem cells back in 2006 showed that Wharton’s jelly derived MSC’s have superior proliferation and differentiation potential compared to bone marrow derived cells. Dr. Deb Muth 05:48They’re like comparing a 20-year-old athlete to a 50-year-old athlete. Both can perform, but one has more reserve capacity, more vigor, and more regenerative potential. And this isn’t this is very important because the perinatal sources umbilical cord tissue Wharton’s jelly amniotic tissue these are what many regenerative medicine clinics in the United States are using today and they’re using them because these tissues are incredibly rich in not just stem cells but growth factors cytoines and exoomes. Dr. Deb Muth 06:21Then there are embryionic stem cells. These are pur potent and they become any cell type in the body, but they’re highly regulated, ethically controversial, and honestly, they’re not being used in clinical practice in the United States outside of the very specific FDA approved research trials. Dr. Deb Muth 06:41So, when clinics talk about stem cell therapy, they’re almost never talking about embryionic stem cells. Now, here’s where it gets interesting and this is the part that changes everything about how we understand regenerative medicine. When you receive stem cell therapy, let’s say someone injects umbilical cord derived messenymal stem cells into your arthritic knee, those cells do not typically engraft or become new tissue in any permanent way. Dr. Deb Muth 07:12They don’t set up shop in your joint and start cracking out new cartilage cells for the rest of your life. So what are they actually doing then? Well, in 2011, researchers Arnold Arnold Kaplan and Dennis Korea published a landmark paper in stem cells translational medicine that fundamentally changed how we understand MSC therapy. Dr. Deb Muth 07:35They proposed that we should stop calling memal stem cells and start calling them medicinal signaling cells. Why? Well, because their primary therapeutic benefit doesn’t come from what they become. It comes from what they secrete. Think of stem cells as incredibly sophisticated biological pharmacies. When you inject them into damaged tissue, that arthritic knee, that inflamed autoimmune condition, that injured brain, that don’t just sit there passively, they sense the environment. Dr. Deb Muth 08:07They detect inflammation. They recognize the tissue damage and they understand that the immune dysregulation is present and they see that and respond. They start pumping out hundreds of bioactive molecules, growth factors that tell your cells to repair and rebuild, cytoines that modulate inflammation, chemocines that recruit your body’s own healing cells to the area. Dr. Deb Muth 08:32And these tiny membranes bound packages called extracellular vesicles, including exosomes, which we’re going to talk about extensively today as well. These secreted factors are giving instructions to your native cells. They’re saying, “Let’s reduce inflammation. Let’s modulate your immune response. Let’s promote angioenesis. Dr. Deb Muth 08:53” That’s the formation of new blood vessels, bringing nutrients and oxygen. Let’s stimulate your own resident stem cells to wake up and get to work. Reduce cell death in damaged tissue and restore normal cellular function. This is called paracrine signaling. It’s the cellto cell communication. And this is where the real therapeutic power lives. Dr. Deb Muth 09:14The stem cells themselves, many of them die within days to weeks, but the cascade of healing they trigger, the signals they send, the programs they activate in your own cells, those effects can last for months or even years. Now, this understanding is crucial because it explains why both stem cell therapy and exoo therapy can be effective. Dr. Deb Muth 09:38The stem cells are powerful not because they become new tissue but because of the signals they send and exoomes are those signals isolated and concentrated. The biggest misconception in regenerative medicine is that stem cells replace tissue and in reality they coach healing more than they become healing. They’re biological educators teaching your body to remember how it used to heal before chronic inflammation, toxicity, and disease turned off all those programs. Dr. Deb Muth 10:12So if stem cells don’t exactly end graft and become the new tissue, if their power is in their signaling and then next logical question is why do we need the cells at all? Well, if we could isolate the messengers themselves, what if we could deliver just the communication systems without any of the complexity of the living cells? Well, that’s exactly what exosomes are. Dr. Deb Muth 10:38And they represent the cutting edge of regenerative medicine. So, let me paint you a picture of how cells actually communicate. Because for most medical history, we had it wrong. For decades, textbooks taught us that cells talk to each other in two basic ways. through direct contact like shaking hands or releasing signaling molecules that floated through the extracellular space like messages in bottles, simple chemical messages. Dr. Deb Muth 11:09But in the 1980s and 90s, researchers started discovering something far more sophisticated. cells were releasing these tiny membrane bound packages like a biological FedEx envelope kind of you know it was filled with complex specific cargo and these packages could travel through the blood cross the barriers that normally keep things out like bloodb brain barrier and deliver their contents to distant cells with remarkable precision. Dr. Deb Muth 11:38These are called extracellular vesicles. And exoomes are one of the most therapeutic important types. So what exactly are exosomes? Well, they’re nanosized vesicles, typically 30 to 150 nanome in diameter. To put that into perspective, a human hair is about 100,000 nanometers wide. These are incredible and most impossibly tiny. Dr. Deb Muth 12:09They’re released by virtually all cells in the body, but the most therapeutically interesting exoomes come from mezenymal stem cells. And those medicinal signaling cells we just discussed. And according to a landmark review of Raposo and Stervogal, they published in the journal of cell biology in 2013, exoomes are not cellular debris. They’re not waste products. Dr. Deb Muth 12:35They are precisely engineered communication vesicles or vehicles. Think of them as sophisticated delivery systems carefully packed, carefully labeled, and sent to specific destinations. very specific instructions. Inside each of these exoomes, you’ll find an incredibly sophisticated payload. They are microRNAs. These are small RNA molecules that can literally turn genes off or on in the recipient cells. Dr. Deb Muth 13:06They can tell a cell to start making more collagen, to reduce inflammatory proteins, to activate repair programs that have been shut down by chronic disease for a very long time. There are messenger RNAs, actual templates for protein production. And exoome can deliver these instructions for making healing proteins. There are proteins themselves, growth factors, cytoines, enzymes, all the molecular tools a cell needs to heal. Dr. Deb Muth 13:34And there are lipids, specialized fats that help the exoome membrane fuse with targeted cells, delivering the cargo inside. When an exoome reaches its target cell, it can either fuse the cell membrane and deliver its contents directly inside like a Trojan horse, or it can bind to surface receptors and trigger signaling cascades, setting off a chain reaction of healing responses. Dr. Deb Muth 14:01Either way, it’s delivering very specific targeted instruction. And here’s what makes this so powerful. Those instructions are tailored to what this recipient cell actually needs. So, let me give you some concrete examples of what the research actually shows because this is where it really gets exciting. When researchers inject MSC derived exoomes into hearts that had experienced eskeeia, reprofusion, injury, that’s damaged blood flow being cut off and then being restored. Dr. Deb Muth 14:36Kind of like what happens during a heart attack. Something remarkable happened. A study by Lei and colleagues published in stem cell research in 2010 showed that exoomes significantly reduced the size of the damaged area, reduced inflammatory cytoines that drive tissue destruction and promoted tissue repair signaling. The exoomes were telling the heart cells stop the inflammatory cascade, activate your survival programs and repair the damage. Dr. Deb Muth 15:06In cartilage research, tow and colleagues published work in biioaterials in 2017 showing that exosomes derived from MSC’s could promote cartilage regeneration in osteoarthritis models. And the exoomes carried specific microRNAs that told condondroytes cartilage cells to proliferate and make more extracellular matrix, the structural framework of healthy cartilage. Dr. Deb Muth 15:30for autoimmune conditions. Research by Blazic and colleagues in Frontiers in Immunology in 2014 demonstrated that MSC derived exoomes could shift immune cell behavior from pro pro-inflammatory to regulatory. They could take an overactive self-attacking immune system and restore balance and promote tolerance. And perhaps most exciting brain research, a study by Zinn and colleagues published in the journal of extracellular vesicles in 2013 showed that MSC derived exoomes could cross the bloodb brain barrier. Dr. Deb Muth 16:07That protective shield around your brain that normally keep things out and promote neurological recovery in stroke models. They reduced brain inflammation, promoted neuroplasticity, supported the formation of neural connections, and for mitochondrial dysfunction, which underlies so many chronic conditions, Morrison and colleagues published research and scientific reports in 2017 showing that MSC derived exoomes can actually deliver functional mitochondria or mitochondrial components to damaged cells. They’re not Dr. Deb Muth 16:40just sending instructions, they’re sending spare parts. They’re restoring the cellular powerhouses to produce energy. So why are exoomes fundamentally different from stem cells? Well, exoomes contain no living cells. They can’t replicate. They can’t end graph. And they have virtually no risk of immune rejection or tumor formation. Dr. Deb Muth 17:03Concerns that exist elevate rarely with cellular therapies. They’re essentially biological software updates for your cells. As Fineian Pitiger wrote in their seinal review in stem cells in 2017, MSC derived exoomes represent the active ingredient of stem cell therapy delivered in a cellfree format. That’s the key insight in the in the therapeutic benefit of stem cells and it comes from what they excrete. Dr. Deb Muth 17:33Then exoomes are the secretion isolated, concentrated, and standardized. From a practical clinical standpoint, exoomes offer several compelling advantages. First, consistency. Because exoomes can be isolated, characterized, and standardized, each dose can be remarkably consistent. With living stem cells, there’s variability based on donor age, health status, processing methods, and one batch may be robust, but another might be weaker. Dr. Deb Muth 18:05With exoomes, you can measure the content, measure the potency, and ensure the quality control. Second is storage. Exoomes can be liophalized. They can be freeze-dried and stored at room temperature or refrigerated for extended periods. Stem cells require cryopreserv preservation, careful freezing, careful thawing. They’re fragile. Dr. Deb Muth 18:31Exoomes are remarkably stable. And third, their safety profile. Without living cells, the risk of adverse imunological reactions is dramatically lower. You’re not introducing foreign cells that your immune system might recognize and attack. You’re introducing molecular messages. Fourth is scalability. You can harvest millions, even billions of exoomes from stem cell cultures without ever injecting the cells themselves. Dr. Deb Muth 19:01And you can produce large quantities, standardize them, and make them available to patients. Now, there is a caution here in doing this. The scalability can produce rogue cells, and we want to be cautious of that. So, here’s what I need you to understand. Exoomes don’t force healing. They remind the body how healing works. Dr. Deb Muth 19:24They’re not replacing damaged cells. They’re re-educating the cells you already have. They’re turning back time on the biological programs that got turned off by inflammation, toxicity, trauma, time, and chronic disease. Your body knows how to heal. It’s done its entire life. Every cut that closed, every bone that mended, every infection you fought off, your body orchestrated that healing. Dr. Deb Muth 19:51The problem is that chronic disease, chronic inflammation, toxic exposures, poor nutrition, stress, all of these things disrupt the communication networks that coordinate healing. And exoomes restore that communication. They’re like rebooting a computer that’s frozen. They reset the system and remind it how it’s supposed to function. All right. Dr. Deb Muth 20:14So, this would not be complete if we didn’t talk about regulation because this is where a lot of confusion exists. And I want you to be given a real picture. Not fear-mongering, not pretending. There aren’t regulatory considerations, but the actual practical reality of how regenerative medicine is practiced in the United States today. Dr. Deb Muth 20:38Here’s what you need to understand. The FDA regulates these therapies and they have specific frameworks, but there’s important nuances between regulatory text enforcement priorities and actual clinical practice. And there are also state level regulations that provide additional pathways. The FDA regulates human cells, tissues, and cellular and tissue based products. Dr. Deb Muth 21:05We call them HCT/PPS under two main pathways. Section 361 products are those that meet specific criteria. They’re minimally manipulated, intended for homologous use, meaning these tissues perform the same basic function in the recipient as it did in the donor. They’re not combined with non-tissue components and they’re either autotogus, meaning they come from your own tissue, or they have had minimal systemic effect. Dr. Deb Muth 21:38An example of a clear 361 procedure, your doctor harvests your own bone marrow, we call this PRP, performs minimally processing to or uh perform Yeah. performs minimal processing to concentrate the stem cells through a centriuge and injects it into your arthritic knee the same day. That’s autogus same day but minimally manipulated. Dr. Deb Muth 22:04This is unquestionably legal and is being done in regenerative medicine clinics across the country every single day. So there’s section 351 where products are those that don’t meet all the section 361 criteria. They’re classified as drugs or biologic products and they require FDA approval through clinical trials. Dr. Deb Muth 22:27Now here’s where this gets more nuanced. There are regenerative medicine clinics across the United States using stem cell and exoome therapies in different contexts. First FDA registered clinical trials. These are formal research studies with investigational new drug applications. Patients enroll in trials. They sign informed consents. Dr. Deb Muth 22:48They receive therapies as part of their structured research protocols. And this is completely legal and represents the gold standard for gathering evidence. Second is observational studies and registry programs. Many clinics are collecting systemic data on patient outcomes using these therapies even outside the FDA trials. Dr. Deb Muth 23:12They’re documenting results, tracking safety, and contributing to the growing body of clinical evidence. Third, there’s clinical practice under physician discretion. There are physicians using these therapies based on their own clinical judgment informed consent from patients and their interpretation of the regulatory framework particularly around minimal manipulation and homologous use. Dr. Deb Muth 23:34Now there are also state regulations that provide additional legal frameworks. So, for example, Florida has enacted the Right to Try Act and specific regenerative medicine legislation that allows physicians to offer certain stem cell therapies under the state oversight. Utah has passed similar legislation creating pathways for regenerative medicine products. Dr. Deb Muth 23:57And these state laws recognize that patients should have access to potentially beneficial therapies, particularly when used by trained physicians with appropriate informed consent. The regulatory question often centers around are these products minimally manipulated. Some products clearly are not. They’ve been cultured. Dr. Deb Muth 24:20They’ve been expanded in laboratories and those require FDA approval that they don’t have. The FDA has appropriately shut down clinics using those products. But there are other products that undergo processing that many physicians and manufacturers argue constitutes minimal manipulation. And these tissues are cleared, potentially fragmented or particulated to make them more suitable for injection, preserved using methods like cryopreservation or liophalization and packaged. Dr. Deb Muth 24:54But the cells are not cultured or expanded in the laboratory. The FDA has issued guidance suggesting that many of these processing steps constitute more than manipul minimal manipulation. But many physicians, particularly those who specialized in regenerative medicine for years, disagree with that interpretation and they believe that the processing qualifies as minimal manipulation and that the product should fall under section 361 when used for homologous purposes. Dr. Deb Muth 25:24Is there regulatory debate? Absolutely. The FDA and some clinicians have different interpretations of what constitutes minimal manipulation. But here’s the practical reality. There are hundreds of well-trained, bore certified physicians across the United States offering these therapies every single day. Dr. Deb Muth 25:42They’re doing so based on their understanding of the regulations, their clinical experience, their commitment to patient safety, and their belief that these therapies can help people who have exhausted conventional options. The FDA’s enforcement priorities have focused primarily on the most problematic cases. Clin clinics making blatant disease cure claims, products with documented safety issues, clear cases of cellular expansion and culture, or clinics operating with no medical oversight. Dr. Deb Muth 26:15Reputable regenerative medicine physicians are using products from companies that provide comprehensive documentation of their processing methods. third-party sterility testing, certificates of analysis showing bioactive content, and quality control measures that meet or exceed industry standards. Now, let me be very clear about something. Dr. Deb Muth 26:36Quality matters enormously. Not all stem cells and exoome products are created equal. Research by Burger and colleagues published in the Orthopedic Journal of Sports Medicine in 2021 analyzed 12 commercially available stem cell products and found that many contained zero viable cells, high levels of bacteria, endotoxins and inconsistent growth factor concentrations. Dr. Deb Muth 27:01This is why the company providing these biologic matters tremendously. You want products from manufacturers who provide transport documentation in sourcing and processing. Conduct third-party testing and sterility and potency. Offer certificates of analysis for each batch. Use standardized validated processing protocols. Dr. Deb Muth 27:24Have quality control measures that ensure consistency and don’t make outrageous cure claims or promise. The best regenerative medicine physician carefully vet their suppliers. They don’t use products from companies making unrealistic promises. They use products from manufacturers who are transparent, scientifically rigorous, and committed to quality. Dr. Deb Muth 27:46Now, you specifically ask about homologous use and collagen defects. So, let me address this directly for you. Under the FDA guidance, homologous use means the tissue performs the same basic function in the recipient as in the donor. So for connective tissue, tendons, ligaments, cartilage, fascia, all of that which are collagenrich structures using MSC’s or their derivatives could be considered homologous use. Dr. Deb Muth 28:17MSC’s in their native environment provide structural support to produce extracellular matrix including collagen. Using them to support healing in damaged collagen rich tissues like arthritic joints, torn tendons or degenerative ligaments is arguably the same basic function. So using exoomes derived from MSC’s to support collagen synthesis reduce inflammation and promote tissue healing in the same structures. Dr. Deb Muth 28:46Many practitioners argue this also qualifies as homologous use because you’re supporting the structure and function that MSC’s would naturally support. So here’s the bottom line on the regulatory reality. Regenerative medicine is available in the United States. It’s being offered by highly trained physicians in integrative and regenerative medicine clinics across the country. Dr. Deb Muth 29:11Some therapies are offered in FDA registered clinics and some are offered in observational studies. Some are offered in clinical practice under physician discretion, informed consent, and careful attention to safety. The regulatory landscape is evolving. There are ongoing discussions both federally and state levels about creating clearer pathways for these therapies. Dr. Deb Muth 29:32So, if you choose to go down this road, you want to work with physicians who understand the regulations, who use quality products from reputable manufacturers with rigorous testing and documentation, who are transparent about what they’re using and why, who discuss the current regulatory landscape honestly with you, and who prioritize your safety and truly informed consent above all else. Dr. Deb Muth 29:55This is not a lawless wild wild west. But it is also not as simple as everything is legal and unavailable. It’s a nuanced landscape that requires ethical knowledge. And these practitioners that have this knowledge have got to provide informed patients who understand both the potential benefits and the current regulatory context. Dr. Deb Muth 30:17So let’s have some fun here. Let’s talk about what really matters to you that are listening and that’s what conditions are being supported with these therapies. What does the research show and what are clinicians seeing in actual practice with patients? Because here’s what’s really important. We have both published research evidence and extensive clinical experience. Dr. Deb Muth 30:38And when the two align, that’s when we can feel confident and comfortable about using these approaches. So, let’s start where we have the most substantial evidence. joint health and muscularkeeletal conditions. For arthritis, we have good data. A systemic review by Tan and colleagues published in arthritis research and therapy in 2021 analyzed 20 randomized controlled trials in MSC therapy for knee osteoarthritis. Dr. Deb Muth 31:05They found significant improvements in pain and function particularly in mild to moderate disease. What’s really interesting is when researchers start analyzing whether it was the cells themselves or their secreted factors doing the work. They found that exoomeenriched preparations showed similar benefits to whole cell therapy. Dr. Deb Muth 31:26Now towen colleagues in the biioaterials paper from 2017 demonstrated that MSC derived exoomes could promote cartilage matrix synthesize and reduce inflammation markers. The exoomes carried microarnas that told cartilage cells to make more collagen and proteoglycans, the building blocks of healthy cartilage. Dr. Deb Muth 31:49In clinical practice, physicians are seeing patients with knee, hip, shoulder, and spinal arthritis, experiencing reduced pain, improved function, better motility, and in some cases, measurable improvements in their tissue. I want to share a story here with you because back in 2006, my husband was injured at work. Some of you might have heard me tell this story before. Dr. Deb Muth 32:11Um, he broke two discs in his back and underwent surgery very early on when we started using stem cells. They had put cages and plates in and they used MSC’s to put inside the cage to create a hardened bone so that he could have a fusion and hopefully not have any pain. At the time, what the physician didn’t realize or mistakenly did was he did not put any human bone mixed with these dead cadaavver bone MSC’s. Dr. Deb Muth 32:42And so the MSC’s never grew. They didn’t have anything to grow by. So the plates and the screws just kind of went back and forth for six months before he could see another physician that would look at him differently and understand what actually happened. That was very early on. Today we know so much more than we did before. Dr. Deb Muth 33:01Fast forward to 2014 when my husband was having problems and he couldn’t feel his legs, he couldn’t feel his feet. We decided to undergo uh exoo and stem cell therapy again and we saw a physician in Florida who harvested cells from his bone marrow and his blood and his fat and mixed that all together and then put that back into the back. Dr. Deb Muth 33:27and he had tremendous benefit from it. So, I tell this story because I want you to see the trajectory of how long this has been going on that we’ve been using this and we’re learning as we’re going and things are changing rapidly in this in this world. And so, what we know today and what I’m teaching you today may very well change in a month or six months or a year from now, but we have the foundation at least to understand what is helpful, what is not right now. Dr. Deb Muth 33:54But just be aware that if you’re embarking on exoome or stem cell therapy or MSC’s that you understand that this terrain is going to change. So back to my conversation about what other things can we treat? Well, we can treat tendon and ligament injuries, chronic tennis elbow, Achilles tendonopathy, rotator cuff tears, chronic planter fasciitis. Dr. Deb Muth 34:17These were researched by PA and colleagues in the American Journal of Sports Medicine in 2017 and it showed that bone marrow concentrate injections resulted in improved pain and function compared to steroid injections. Now this mechanism appears to be enhanced collagen remodeling and reduced chronic inflammation. Dr. Deb Muth 34:39These are structural collagenrich tissues using MSC’s or their derivatives for structural support which makes biological sense. It’s homologous use. It’s similar. So clinically we’re seeing athletes, active adults and people with chronic pain who failed physically um failed physical therapy, failed conservative treatments finding relief in this functional uh improvement in this functional world that we live in today. Dr. Deb Muth 35:07So, I want to be clear about what we’re doing here for joint and muscularkeeletal issues. We’re not growing completely new cartilage from scratch or severely destroyed joints. We’re not magically regenerating tissues that’s been gone for decades. That’s not possible here. What you’re doing when you’re using MSSE’s and exoomes is supporting the body’s natural ability to repair, reducing inflam inflammation and damage, and we’re driving progressive degeneration uh or we’re stopping the progressive degeneration. By reducing the Dr. Deb Muth 35:41inflammatory damage, we’re stimulating resonant stem cells that have been dormant. We’re improving blood flow and uh uh oxygen to the tissues like cartilage and tendons. and we’re organizing the body to start creating its own quality collagen as it heals. So, it’s a regenerative support, not a tissue replacement. Dr. Deb Muth 36:07But for many people, this support is lifechanging. So, let’s talk about autoimmune disorders now because this is one of the most exciting and unrecognized applications. autoimmune conditions like rheumatoid arthritis, lupus, MS, Crohn’s disease, ulcerative colitis, Hashimoto’s, they all involve the immune system and the immune system is deregulated. Dr. Deb Muth 36:30And so basically your immune system is seeing this tissue as foreign and it’s attacking it. These MSC’s and their exoomes have profound immune modulatory properties. They don’t suppress the immune system like steroids or imunosuppressive drugs. They modulate it helping to restore balance. So for rheumatoid arthritis, research by Weang and colleagues in stem cells translational medicine in 2016 showed that MSC derived exoomes could shift the balance of immune cells, reducing pro-inflammatory TH7 cells that drive joint disruption uh and increase Dr. Deb Muth 37:08regulatory TE-C cells that maintain immune tolerance. So for MS, a clinical trial by Kasus and colleagues published in archives of neurology back in 2010 evaluated autotogus MSC therapy and MS patients and they found evidence of reduced disease activity, improved neurological function and decreased inflammatory uh lesions on MRI scans. Dr. Deb Muth 37:34The proposed mechanism is MSC’s and their exoomes reduce inflammatory cytoine production promote regulatory imu immune populations support remination of damaged nerves that is rebuilding the protective coating around the nerve fibers and it reduces bloodb brain barrier permeability which prevents immune cells from attacking their brain and spinal cord. Dr. Deb Muth 38:02And so for inflammatory bowel disease, the research by Barnholm uh sorry Barnhorn and colleagues in gut in 2020 showed that MS cell MSC derived extracellular vesicles could support mucosal healing and reduce inflammation in the gut lining. They appeared to restore intestinal barrier function, healing that leaky gut and modulating local immune responses. Dr. Deb Muth 38:30So in clinical practice, physicians are seeing patients with autoimmune conditions, experiencing reduced disease flares, decreasing the need for imunosuppressive medications, improving energy and quality of life, and in some cases extending periods of remission. But here’s what I want you to understand. Dr. Deb Muth 38:52When you see these therapies for autoimmune conditions, we are supporting immune regulation and reducing inflammatory damage. We are not treating or curing the disease in a conventional sense. These therapies work best as part of a comprehensive functional medicine approach that also addresses gut health because 70% of your immune system lives in your gut and environmental triggers like mold, heavy metals, chemical toxins that can drive autoimmune responses, chronic infections that can trigger immune disregulation, stress and nervous system imbalance. And Dr. Deb Muth 39:29these nutritional deficiencies are necessary to help improve the immune function. So regenerative therapy without addressing root causes is like bailing water out of your boat without plugging the hole. You might get temporary relief, but the underlying problem still remains. So let’s talk about neurological conditions. Dr. Deb Muth 39:52And this is where the science gets truly fascinating. for traumatic brain injury and concussion. Research by Zang and colleagues in the Journal of Neurot Trauma in 2015 showed that MSC derived exoomes could reduce brain inflammation, promote neuroplasticity, that’s the brain’s ability to rewire itself and improve cognitive outcomes in animal models. Dr. Deb Muth 40:17The exoomes crossed the bloodb brain barrier, delivered neuroprotective proteins and microRNAs. They reduced inflammation, supported mitochondrial function in injured neurons and promoted both new blood vessels from new blood formation and neurogenesis and the birth of new neurons occurred. Neurological recovery requires a multi-systematic approach. Dr. Deb Muth 40:42Exoomes may support neural repair, but they work best combined with hormone optimization, growth hormone, testosterone, thyroid, pregnnolone, mitochondrial support compounds like NAD, CoQ10, PQQ, carnitine, all of those things that we use traditionally in functional medicine. Now for stroke recovery, there was research by Zinn and colleagues in the journal of extracellular vesicles that showed MSC derived exoomes reduced the size of brain damage and improved neurological recovery in animal models. There was a Dr. Deb Muth 41:19Parkinson’s disease study done by Kimoji and colleagues in the movement disorders in 2018 that suggested that MSSE derived exoomes could support dopamineergic neuron survival and those are the cells that die in Parkinson’s and it can help to reduce neuroinflammation. Clinically, physicians are seeing improvements in patients with postconussion syndrome, chronic traumatic brain injury, early stage cognitive decline, and other neurodeenerative conditions. Dr. Deb Muth 41:52These are not cures, but meaningful improvements in cognitive function, mood, energy, and quality of life. Now, let’s talk about autism spectrum disorder very carefully here because this is a very sensitive but very important topic for families. There have been several clinical trials that have explored MSC therapy for autism. Dr. Deb Muth 42:16Liv and colleagues published research in stem cell translational medicine in 2013 showing improvements in social interaction, communication, and behavioral symptoms in children with ASD who received cord blood MSC’s. Dawson and colleagues in 2017 conducted randomized trial autotogus cord blood infusion and found modest improvements in social communication particularly in children with higher baseline immune dysregulation. Dr. Deb Muth 42:47The proposed mechanisms for modulation of neuroinflammation support the mitochondrial function because many children with autism show evidence of mitochondrial dysfunction, reduction of oxidative stress, improvement in gut brain access dysfunction and modulation of immune dysregulation. In clinical practice, some physicians are seeing improvements in some children, better eye contact, increased language development, reduced sensory sensitivities, improved social engagement, but responses vary significantly, and we cannot predict which children will benefit most. So for Dr. Deb Muth 43:26families considering regenerative approaches for autism, these therapies are supporting the body’s healing mechanisms, reducing neuroinflammation, supporting cellular energy production, modulating immune function. These should only be considered as part of a comprehensive biomedical approach that includes dietary interventions to address food sensitivities, support gut health, environmental toxin removal, particularly heavy metals and chemical exposures, gut healing protocols with targeted probiotics and nutrients, Dr. Deb Muth 44:00metabolic testing and targeted supplementation, and evidence-based on behavioral and developmental therapies. These therapies should only be pursued with practitioners who are honest about what we know and what we don’t know and who follow rigorous safety protocols who never promise cures and who view regenerative medicine as a tool in the comprehensive healing strategy, not a standalone miracle. Dr. Deb Muth 44:26Not only that, these therapies will most likely need to be given several times over the course of this person’s lifetime, possibly even on an annual basis. And this is really important because it is not a oneandone. It is not a one-sizefits-all, and it needs to be looked at as a long-term option for working with autism. So, since we’re looking at stem cells versus exoomes, living cells, with stem cell therapy, you’re receiving living cells that can survive in your body for days to weeks. Dr. Deb Muth 45:02With exoome therapy, there are no living cells, just biological messages they would have sent. So, replication stem cells can potentially replicate. Although therapeutically this happens minimally, exoomes cannot replicate. They deliver the cargo and then they are cleared by your body. With stem cells, it’s primarily paracrine signaling. Dr. Deb Muth 45:28They’re coaching your cells to heal. With exoomes, it’s pure signaling, pure reprogramming your cells without any cellular component. Stem cells as we talked about can be autotogus from your own bone fat, blood or um bone marrow or allergenic from umbilical cord tissue or Wharton’s jelly. Dr. Deb Muth 45:50Exoomes are typically derived from cultured MSC’s often from umbilical cord or bone marrow sources and both can be given by local injection for targeted treatment of joints and tissues and exoomes can be given intravenously for whole body systemic support. both have um low immun immunogicity. I can’t say that word today. Dr. Deb Muth 46:17But exoomes have even lower risk since they contain no cellular material. Now, it’s absolutely critical for you to understand that there are massive quality differences. We’ve talked about this earlier. I want you to be very aware of this and have a conversation with any of the practitioners that you’re considering undergoing this treatment with. Dr. Deb Muth 46:37Here is where it matters more than anything when you’re considering regenerative medicine, the quality of the products and the expertise of the practitioner. Because the reality is not all regenerative medicine products are created equal. We all know that when we take different supplements and not all practitioners understand these therapies at the same depth. Dr. Deb Muth 46:58You want to look for practitioners that are board certified or have some kind of specialized regenerative medicine training. You want to know their clinical experience. How much have they done these procedures? How long have they done this? You want honest communication about the evidence and the limitations in this. Dr. Deb Muth 47:17You want a comprehensive functional medicine approach to go along with these therapies. And you want somebody that’s transparent about their informed consent and their regulatory status. If you have people that are uh claiming that they can cure disease or giving you guarantees, that is not that is not a good practitioner to work with. Dr. Deb Muth 47:37If you have high pressure sales tactics, you need to decide today limited supply for a week. These are marketing manipulations. It’s not medical care. You want to be cautious of extremely low prices because quality regenerative products are expensive to source, process, and test. and store. And if somebody’s offering stem cells or exoomes for a few hundred dollars, seriously, you need to question the quality, the safety, and where they got this from. Dr. Deb Muth 48:09So before undergoing any regenerative therapy, make sure you’re having a very, very lengthy conversation with the person and so you truly understand exactly what you’re getting, how it’s going to be delivered, and what they’re going to do. If there’s one thing I want you to take away from today is that your body has remarkable capacity to heal when given the right biological signals and the right environment. Dr. Deb Muth 48:35Stem cells and exoomes are powerful tools for providing biological signaling that can reduce inflammation, modulate immune function, support tissue repair, and restore cellular communication that’s been disrupted by chronic disease and inflammation. These therapies are available in the United States through trained physicians working in FDA registered trials, observational studies, and clinical practice, and using quality products from manufacturers with rigorous testing and quality control. Dr. Deb Muth 49:04So before you invest in regenerative medicine, do your homework. Ask detailed questions about product quality and source. Verify the products come from reputable manufacturers with certificates of analysis, third-party testing. Work with experienced practitioners. And remember, no injection, no infusion, no biologic can overcome ongoing toxic exposure, chronic stress, poor nutrition, gut dysfunction, and inadequate sleep. Dr. Deb Muth 49:34True healing requires your body and you to actively participate in this healing. If you are unwilling to address the root causes and change the lifestyle factors that disrupted your health in the first place, the biologics can amplify your healing signals, but you have to create the internal environment where healing can actually happen. Dr. Deb Muth 49:56So, I hope this episode has helped you understand regenerative medicine more clearly. Share it with somebody who’s looking for healing beyond the conventional approaches. And until next time, this has been Let’s Talk Wellness Now. Have a blessed day. >> Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Dr. Deb Muth 50:16Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided forformational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. Dr. Deb Muth 50:41While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Your use of information from this broadcast is entirely at your own risk. Dr. Deb Muth 51:00By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time, and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 265 – The Future of Healing: How Exosomes Re-Educate Your Body to Heal Itself first appeared on Let's Talk Wellness Now.

durée : 00:02:33 - par : Loïc Pialat, Yann Rousseau - Confrontée à l'exode des jeunes dans les grandes villes et à la chute de la natalité, la préfecture de Kochi, compte payer les abonnements de ses jeunes sur les applications de rencontre. Une initiative pour encourager les mariages et enrayer le déclin démographique. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Avec : Baptiste des Monstiers, grand reporter. Carine Galli, journaliste RMC. Et Jérôme Lavrilleux, propriétaire de gîtes en Dordogne. - Accompagnée de Charles Magnien et sa bande, Estelle Denis s'invite à la table des français pour traiter des sujets qui font leur quotidien. Société, conso, actualité, débats, coup de gueule, coups de cœurs… En simultané sur RMC Story.

You have probably heard of the vagus nerve, and (whether you realize it or not) have been exposed to some of the concepts of Polyvagal Theory in yoga classes. In fact, we have discussed the theory in a previous episode of the podcast. In today's episode, host Rachel Land and Yoga Medicine Therapeutic Specialist Valerie Knopik, PhD, revisit Polyvagal Theory and explore the latest scientific debate it has generated. They break down the original framework, the newer criticisms, and the ways scientific ideas evolve over time.  The conversation stays grounded in real-world teaching, especially around stress response, breath, and the role of relationships in helping people feel safe enough to practice. It is a thoughtful reminder that research can shift while the practical value of awareness, connection, and regulation remains central to yoga. "Science is never stagnant, and that's part of the beauty of science for me." — Valerie Knopik. — What You'll Learn: Vagus nerve roles in stress and relaxation response [3:24] Recent papers updating and challenging Polyvagal Theory (PVT) [4:41] The nature of the scientific method [7:12] Defining PVT [10:37]  Summarizing the current controversy: over-simplification of dorsal vs ventral vagus [25:29] Other points of contention: dorsal vagal and trauma response, heart rate variability as a measure of vagal tone, clinical over-use [31:41] Relevance to yoga teaching and practice [37:11] The "science of safety" in yoga: Yoga Medicine Mental Health & Wellness Teacher Training [44:00] — Links Mentioned: Watch this episode on YouTube Mental Health & Wellness Yoga Teacher Training  Yoga Medicine Podcast Research Roundup: Updates on Polyvagal Theory  Porges SW. Polyvagal Theory: Current Status, Clinical Applications, and Future Directions. Clin Neuropsychiatry. 2025 Jun;22(3):169-184. doi: 10.36131/cnfioritieditore20250301. PMID: 40735382; PMCID: PMC12302812 Grossman P et al. Why The Polyvagal Theory Is Untenable: An international expert evaluation of the polyvagal theory and commentary upon Porges, S.W. (2025). Clin. Neuropsychiatry, 22(3), 169-184. Clin Neuropsychiatry. 2026 Feb;23(1):100-112. doi: 10.36131/cnfioritieditore20260110. PMID: 41768017; PMCID: PMC12937499 Yoga Medicine Podcast Episodes: Epigenetics, Mental Health & Yoga  The Neuroscience of Resilience  Interoception Research & Yoga  Connect with Valerie Knopik, PhD: Facebook | Instagram | X | YMO Teacher Learn More: Find the full show notes at YogaMedicine.com/podcast-166. Learn more about insider tips, online classes or information on our teacher trainings at YogaMedicine.com. To support our work, please leave us a 5 star review with your feedback on iTunes/Apple Podcasts or wherever you listen to podcasts. 

durée : 00:04:58 - Avec sciences - par : Alexandra Delbot - C'est une idée reçue tenace à nouveau battue en brèche. L'analyse génomique de 258 individus inhumés en Germanie romaine révèle une arrivée très progressive de populations nordiques. Dès la première génération après le déclin, les deux peuples se sont mélangés, preuve qu'ils se côtoyaient déjà. - invités : Daniel Wegmann Bio-informaticien de l'Université de Fribourg

durée : 00:02:57 - Le 18/20 : un jour dans le monde - par : Rédaction Internationale - Demain, les élections locales au Royaume-Uni devraient consacrer la débâcle des "vieux partis". - invités : Frédéric Says Journaliste à la rédaction internationale de Radio France Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:02:17 - Une carte qui circule sur X, vue plus de 200 000 fois, oppose le réseau ferré français de 1930 à celui de 2014 pour dénoncer un déclin imputable au "capitalisme". Si les chiffres bruts sont exacts, c'est la façon dont ils sont interprétés sur les réseaux sociaux qui pose problèmes. - réalisation : Armêl Balogog, La cellule Vrai ou faux Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Notre répondeur vocal: https://www.vodio.fr/repondeur/311/Le fou rire, sujet atypique en sexo et très peu documenté. Avez-vous déjà vécu un fou rire après un climax sexuel ? Ou bien vous avez été témoin de fou rire à l'issu d'un climax sexuel ?Avez-vous déjà observé à quel point le fou rire et l'orgasme sont similaires ? Ils procurent tous deux de la joie profonde, de la détente musculaire, la plénitude en toute simplicité. Hors contrôle, spontanés, terriblement bienfaisants. Besoin d'aucun artifice, qu'un corps et un esprit détendu. Les deux phénomènes génèrent pleins d'hormones de bien-être ! La sexualité c'est aussi le rire, le fou rire, la légèreté, la complicité contagieuse. Terriblement contagieuse oserais-je dire. L'esprit curieux, ouvert, léger, observez le cœur capable de se laisser surprendre par un « fou rire sexuel ». Qui sais, cela pourrait vous arriver aussi, à l'improviste évidemment. Le sujet est curieux, mais plein de bon sens, cohérent et magique quand on y pense. Avez-vous déjà entendu parler de la gelatologie… c'est une blague ! Mais bien la gelotologie. L'étude du rire et de ses effets sur le corps ! Voilà un super sujet qui pour les curieu.x.ses de la sexualité. Le podcast propose une brève réflexion sur le sujet. On vous souhaite une belle écoute.Au plaisir de lire ou d'écouter vos retours. Pour les plus curieu.x.se, je vous invite à lire l'article qui joint le podcast sur le site du LHC : https://love-health-center.org/podcast/Merci à The Podcast Factory Org asbl pour la création de cette chaine podcast absolument délicieuse.#PodiBUZ, la marque éditoriale de The Podcast Factory Org asbl-vzwLe partenaire de vos podcasts pro et privés.Séquençage du podcast : [00:00:20] Introduction[00:00:41] Sexualité et fou rire[00:01:29] Un fou rire après l'orgasme[00:02:43] Vibrations et plancher pelvien[00:05:19] Fou rire et détente du corps[00:05:49] Nerf vague et Chi Nei Tsang[00:06:51] Le fou rire est contagieux[00:07:10] Une sexualité plus légère[00:08:51] Émotions et mémoire du corps[00:10:36] Les effets hormonaux du rire[00:11:36] Un phénomène encore peu documenté[00:12:49] Le prochain épisode sur le plaisir prostatiqueQuelques idées : • Pratique de « Chi Nei Tsang » ou d'auto massage inspiré du « Chi Nei Tsang ». Un massage taoïste profond du ventre, issu de la médecine chinoise traditionnelle, qui vise à harmoniser l'énergie (Chi) des organes internes (Nei Tsang). En travaillant sur l'abdomen, considéré comme notre "deuxième cerveau", ce soin libère les tensions physiques, détoxifie le corps et débloque les émotions négatives accumulées. Œuvrer pour soi-même à relâcher, libérer les tensions dans tous les organes de votre ventre, prendre conscience de manière plus précise de votre ventre et ainsi les sensations en lien avec votre génital et votre énergie sexuelle.• Tel le Chi Nei Tsang, en conscience s'auto-masser en douceur délicate les organes internes par la respiration. A chaque inspire, apnée, expire, apnée…etc. Ecoutez notre podcast sur le sujet : https://love-health-center.org/podcast/sexualite-et-respiration-68/• Tonifier et prendre conscience de son propre plancher pelvien. Ecoutez entre autres notre podcast sur le sujet (en anglais, mais sous-titré en plusieurs langues sur Youtube): https://love-health-center.org/podcast/katalin-szupkay-the-pelvic-floor-eng-podcast-entr-nous/• Prendre soin de votre système parasympathique et nerf vague• Pratiquer le yoga du rire• Essayer le massage sonore : https://www.peter-hess-academy.be/Elucubration passionnée : les vibrations sonores dans le corpsElément non mentionné dans le podcast, mais implicite : qui dit son, rire dit aussi vibrations. Ces oscillations délicieuses qui parcourent notre corps de l'intérieur. Saviez-vous que le son se propage beaucoup plus vite dans la matière (eau, os) que dans l'air. Quand on a un fou rire, le son, les sonores et les vibrations mécaniques traversent le corps de toutes parts. Mais simplement aussi, quand on parle, les vibrations traversent le corps très rapidement. Nos cellules sont informées par une micro vibration interne bien plus vite que le monde extérieur via la propagation dans l'air. Imaginez, st si le son et la vibration inaudible qui l'accompagne rebondissait entre la "toile" du tambour du plancher pelvien jusqu'au sommet du crâne, faisant des aller-retours d'échos entre ces 2 "paraboles" de part et d'autre de la colonne vertébrale. Mais aussi jusqu'à la plante des pieds. Certes les tissus mous et les changements de milieux atténuent l'onde, mais elle est néanmoins là. D'autre part, le son et les ondes qui traversent notre corps de haut en bas et de bas en haut massent subtilement au passage les organes, tissus, cellules, liquides qui se trouvent entre ces 2 pôles.(dans l'air (à ~20 °C) le son se déplace à ~343 m/s alors que dans l'eau c'est environ 1480 m/s et encore plus vite dans les solides comme les os, possiblement jusqu'à 3000 - 5000 m/s. Les vibrations se propagent donc directement et très rapidement dans ton corps via les os, et l'os du crâne. C'est ce qu'on appelle la conduction osseuse. Alors, dommage que l'on n'a pas d'os pénien pour expérimenter d'autres curieuses sensations. C'est entre autre à cause de la conduction osseuse que ta voix te semble différente quand tu l'entends enregistrée. J'aime voir les choses et les expériences avec un regard neuf, curieux, apprenant. Certes, le son et les vibrations se propagent vites en faisant des échos, mais sans récepteur (conscient) à quoi bon ? Quoique nos champs subtiles y sont probablement sensibles. Clin d'œil slow sex, la vitesse et la conduction c'est une chose, mais la qualité du son, des mots, des énergies véhiculées en sont une autre ????.Elucubration passionnée : les 3 diaphragmes, plancher pelvien, pulmonaire, et …Connaissez-vous le diaphragme sellaire ? C'est une petite membrane horizontale formée par une extension de la dure-mère (la couche la plus externe des méninges) située dans une dépression osseuse du crâne appelée la selle turcique. Cette membrane recouvre partiellement une structure clé : l'hypophyse (glande pituitaire). Glande endocrine essentielle en sexualité. Ce diaphragme participe à la compartimentation des espaces contenant le liquide céphalorachidien. Ce liquide est pour moi intimement lié aux éveils des sensations sexuelles. Non excité ce liquide est probablement moins chargé en électrolytes, que lorsqu'on est excité sexuellement suffisamment longtemps, ce liquide (présent tout le long de la colonne vertébrale) reçoit possiblement une partie des secrétions hormonales de plaisir sexuelle rendant sa conductivité et ses propriétés physiologiques tout autre. Bref, on pourra en parler une autre fois. Concernant les vibrations, les vibrations de son, de fou rire, font certainement vibrer cette membrane au niveau du cerveau. Un champ d'exploration et de découverte possiblement intéressantes dans les décennies à venir, qui sait ? Quoi qu'il en soit, vive les fou rires. Car avant tout, c'est simple, puissant, délicieux et c'est déjà largement suffisant.Bon voyage aventuriers et aventurières de la vieLe rire peut être une raison supplémentaire pour développer une vie sexuelle encore plus épanouissante. Développer la légèreté, l'humour, l'espièglerie, le fun, le jeu, les moments délicieusement absurdes, le lâcher-prise, l'audace amusante… La sexualité ce n'est probablement pas être sérieu.x.se, dogmatique, coincé, triste ou mental, mais ce n'est qu'un point de vue dans un monde où la liberté revient à chacun.e d'être créateur de sa vie (et vie sexuelle). De là, bonne route à chacun.e. Vive le sourire aussi et tous ses magnifiques effets.On vous souhaite expansion, fou-rires et état d'orgasme. Connectez-vous à notre chaine de podcast si vous le souhaitez (ça nous aide à être visible de plus d'humain) et à votre sourire intérieur comme un lien intime et réel avec votre énergie sexuelle.

Avec : Pierre Rondeau, économiste. Élise Goldfarb, entrepreneure. Et Frédéric Hermel, journaliste RMC. - Accompagnée de Charles Magnien et sa bande, Estelle Denis s'invite à la table des français pour traiter des sujets qui font leur quotidien. Société, conso, actualité, débats, coup de gueule, coups de cœurs… En simultané sur RMC Story.

durée : 00:02:12 - par : Emmanuel Cugny - Une étude, qui vient d'être publiée, ne fait pas les affaires du secteur de la construction. Selon le cabinet de conseil Xerfi, d'ici 25 ans, la baisse des naissances devrait réduire la taille des ménages et entraîner un net recul des constructions neuves. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Neal warns scout leaders about their responsibility regarding the eventual death of the sun, demands a compulsory national bone registry for dog owners. issues a stark warning about tiny front gate book libraries, tries to figure out how fishes reproduce, looks at a problematic character on Criminal Minds, staunchly defends so called light pollution, asks if dogs can commit crimes of passion, considers installing an artificial meadow in your sitting room, explains why your subconscious might be successfully fighting off criminal charges while you sleep, recalls the laziness of Stanley Kubrick’s 2001: A Space Odyssey (1968), looks at the miracle of synchronised winking, wonders about night court opening hours, remembers an underground Billy Bunter book lending operation, wonders how surgeons navigate your horse’s spacious Interior and discvusses illicit drugs in dog prison, microwave popcorn, the back seat of a horse, adult candy cigarette addiction, how vets and clerics bamboozle you with Latin, Clin-ons, cling film, how a simple cardboard chimney could make you a better parent, the short lived Coca Cola Life, the Wild West versus Ireland’s west, Gangs of New York (2002), the trouble with Irish people on Star Trek, Colm Meany, Ireland’s tea minstrel lottery that nobody realised was appalling, Noddy by Enid Blyton, how cut-out coupons risk structural integrity. a third way to enjoy The Sixth Sense (1999), frogs versus toads, tennis versus badminton. a fifteen week school screening of MIssissisipp Burning (1989), the scout camping experience, the power cut cooking experiences=, trying to be frivulous, trying to pronounce frivulous, trying to spell, how to know whether you’re alive and more. VISIT IntoYourHead.ie for everything and more. IN THE FAR FUTURE? Feeds broken? Site dilapidated? Everyone dead? No problem! Find hundreds of Into Your Head shows and Matchstick Cats comics on Archive dot org. LICENSE: Creative Commons BY-NC-ND 4.0 – Attribution: Neal O'Carroll.

durée : 00:04:31 - Avec sciences - par : Alexandra Delbot - Le déclin des insectes reste encore mal documenté. Pour combler ce vide, le projet "Bugs Matter" mise sur les sciences participatives : il suffit de télécharger l'application, de bien nettoyer sa plaque d'immatriculation puis de la photographier après le trajet. - invités : Grégoire Loïs Ornithologue, naturaliste au MNHN et directeur adjoint du programme de sciences participatives “Vigie-Nature”

Dans cette conférence du congrès du bien commun, Julien Langella analyse les défis majeurs auxquels la jeunesse française est confrontée. Il aborde le déclin anthropologique, la disparition progressive de notre culture, l'omniprésence des écrans et des jeux vidéo, ainsi que les dérives du pédagogisme au sein de l'Éducation nationale. Langella plaide pour une refonte de notre système éducatif, en mettant l'accent sur la formation de maîtres exemplaires capables de transmettre une éducation intégrale. Découvrez comment reconstruire une société solide en redonnant à l'éducation la place centrale qu'elle mérite.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Tous les jours dans la matinale d'Europe 1, Olivier de Lagarde scrute et analyse la presse du jour.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Surnommée le "Vieux Continent", par opposition au "Nouveau Monde", l'Europe n'a sans doute jamais aussi bien porté son nom. En 2025, l'Union européenne compte un peu plus de 450 millions d'habitants, mais sa population pourrait fortement chuter dans les années à venir.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

Je papillonne

L'arrêt de la production à Poissy illustre la fragilisation d'un secteur clé de l'économie française. Entre perte de compétitivité, mutations technologiques et concurrence mondiale, c'est l'avenir même de notre industrie qui se joue.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

durée : 00:03:18 - Géopolitique - par : Pierre Haski - Les États-Unis sont-ils une superpuissance en déclin, et la guerre bâclée en Iran est-elle l'équivalent de la guerre de Suez en 1956 pour la France et le Royaume-Uni, qui a vu leur leadership s'effacer ? Les analogies historiques ont leur limite, mais elles aident à réfléchir sur l'état du monde. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

durée : 00:03:18 - InterNational - par : Pierre Haski - Les États-Unis sont-ils une superpuissance en déclin, et la guerre bâclée en Iran est-elle l'équivalent de la guerre de Suez en 1956 pour la France et le Royaume-Uni, qui a vu leur leadership s'effacer ? Les analogies historiques ont leur limite, mais elles aident à réfléchir sur l'état du monde. Vous aimez ce podcast ? Pour écouter tous les épisodes sans limite, rendez-vous sur Radio France

Depuis plusieurs mois, les tensions entre la France et l'Algérie sont au plus haut. Une illustration de la crise globale que traverse Alger ces dernières années, entre affaiblissement sur la scène diplomatique, difficultés économiques et contestation du pouvoir en place. Dans cette série, on vous raconte les défis de l'Algérie d'aujourd'hui. Pour ce deuxième épisode, Charlotte Lalanne, journaliste au service Monde de L'Express, s'intéresse au déclin géopolitique d'Alger. L'historien Pierre Vermeren, professeur à l'université Paris 1 Panthéon-Sorbonne, spécialiste du Maghreb, auteur d'une Histoire de l'Algérie contemporaine, de la régence d'Alger au Hirak (XIX-XXIe siècles) (Poche Nouveau Monde Éditions), apporte également son éclairage. Retrouvez tous les détails de l'épisode ici et inscrivez-vous à notre newsletter. L'équipe : Écriture et présentation : Charlotte Baris Réalisation : Jules Krot Crédits : TF1, Le Nouvel Obs Musique et habillage : Emmanuel Herschon / Studio Torrent Logo : Jérémy Cambour Pour nous écrire : laloupe@lexpress.fr Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Tipeee : https://fr.tipeee.com/tatami-connexion/Import Fight : https://import-fight.com/?srsltid=AfmBOorPLaRoGMlD5TMi_ToZnEBnkq6Mr3p_RFLl7lU5Idm0R0ySUfQdCode : TATAMI10Bienvenu sur le format actualité MMA et JJB du podcast TATAMI Connexion : Restons Connecté !Chaque semaine nous allons parler des sujets qui anime nos sports et qui attise toutes les conversation !Cette semaine programme chargé avec :- Adesanya vs Pyfer- Le KO de Grasso- Tsarukyan de retour cet été- Doumbé de retour mais pas en mma - Shevchenko répond à Khabib- Un biopic sur GSPBonne écoute !!

Clin d’oeil à SIGH et MAGANE (anciens Mortes Saltantes). On commence d’ailleurs par eux (Magane) suivis des compères Abigail, Sungoddess… Et profitons du travail de Sakrifiss et de Thrashocore pour répertorier et faire des petites fiches sur le black metal nippon.Place à Misogi, puis Sigh, Sabbat fermant la marche, avant le « marqueur ». On poursuit avec […] L'article LJDH – Izanafi Infidel Art est apparu en premier sur Radio Campus Tours - 99.5 FM.

Merci à notre commanditaire ProCafetière : https://tinyurl.com/procafetiere-jerrPour obtenir le Café Whats Up :https://procafetiere.ca/collections/cafe-vrac/products/espresso-whats-up-cafe-vracUtilise le code JERR20 pour 20% de rabais sur le sac Whats Up ;) Figure incontournable du paysage culturel québécois, Patrice L'Écuyer m'a fait l'honneur d'être l'invité du Whats Up Podcast. En plus de 45 ans de carrière, il a partagé des anecdotes savoureuses des coulisses de la télé : des tentatives de triche lors de quiz aux entrevues marquantes avec Plume Latraverse et à ses débuts de collaboration avec Mike Ward.Au-delà des rires, l'animateur a également abordé des enjeux plus sésrieux : la réalité d'un milieu marqué par les égo et le déclin progressif du modèle télévisuel traditionnel. Un échange de 90 minutes à la fois drôle et captivant. Enregistré le 17 Février 2026. Site officiel de Patrice L'Écuyer :https://patricelecuyer.com/dates-de-spectacle/ Pour devenir membre et supporter le Whats Up Podcast : https://www.patreon.com/whatsuppodcast Merci les patreon !!Site web officiel :https://jerrallain.com/Pour suivre Jerr sur Instagram : https://www.instagram.com/jerr_allain/Pour suivre Jerr sur facebook : https://www.facebook.com/JerrAllainofficielContact : jerr.production@gmail.comPour vous abonner à mon Infolettre : http://eepurl.com/hvpnhj

Clin d’oeil à Unbounded Terror bien sûr. Dans cet épisode, on va en Espagne en quête de death metal. Absorbed ouvre le bal, suivi de Necrophiliac, Unbounded Terror donc, Repugnance (et attention, l’auteur du bouquin « Total Virulence » sur la scène espagnole, c’est Fredo De La Roza, pas Gaza), Aposento (2 fois), Feretrum (réédition par Memento […] L'article LJDH – Nest Of Affliction est apparu en premier sur Radio Campus Tours - 99.5 FM.

With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital-  Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1.     Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2.     Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3.     Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4.     Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

durée : 02:29:49 - Les Matins - par : Guillaume Erner, Yoann Duval - Ce matin, sur France Culture, à 7h40, Guillaume Erner reçoit le journaliste libanais Anthony Samrani et le professeur Karim Emile Bitar pour analyser la guerre en Iran et ce qu'elle fait au Liban. À 7h17, le chercheur Florent Parmentier revient sur la crise entre l'Ukraine et la Hongrie. - réalisation : Félicie Faugère

Clin d’oeil à VENIN, combo hard rock/heavy metal marseillais, vétéran des années 80, qui se produisait au bar Le Jéricho, le 28 février 2026, en compagnie de Lord Gallery (heavy metal avec des poussées de speed/thrash, ce n’est pas le patch ou le dossard Dark Angel d’un des musiciens qui me contredira).  En tout cas […] L'article Maggot Brain – Trafiquants de Rock est apparu en premier sur Radio Campus Tours - 99.5 FM.

This inaugural episode of the CardioNerds Pulmonary Embolism (PE) Series explores the evolution of acute PE care. Dr. Ibrahim Zahid, Dr. Dinu Balanescu, and Dr. Billy Joe Mullinax join guest expert Dr. Kenneth Rosenfield to discuss the shifting landscape of PE management. Pulmonary embolism (PE) remains a leading cause of cardiovascular mortality and a frequent diagnostic challenge, often masquerading as myocardial infarction or a benign illness. Over the past decade, PE care has evolved from anticoagulation-only strategies to nuanced, risk-stratified, multidisciplinary management. Modern approaches integrate hemodynamics, biomarkers, and advanced imaging to guide therapy, including catheter-directed interventions and large-bore thrombectomy. The Pulmonary Embolism Response Team (PERT) model addresses historical gaps by coordinating rapid, multispecialty decision-making and standardizing care pathways. The PERT Consortium further advances PE care through education, research, and the world's largest PE registry, while fostering leadership and research opportunities for trainees. Despite advances, long-term outcomes and post-PE syndromes remain important areas for future investigation. Audio editing by CardioNerds Academy intern, student doctor, Pace Wetstein. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Pulmonary Embolism PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls PE is a “master masquerader”—maintain suspicion for atypical presentations like myocardial infarction, heart failure, flu, or anxiety. Multidisciplinary management mediated through pulmonary embolism response teams improves outcomes and standardizes care. Risk stratification integrates hemodynamics, biomarkers, and imaging. Advanced therapies have expanded beyond anticoagulation. Long‑term follow‑up and post‑PE syndrome need more research. Notes Notes: Notes drafted by Dr. Ibrahim Zahid. 1. How has the clinical approach to PE changed over the past decade? PE is the third leading cause of cardiovascular death and historically under‑recognized. Symptoms mimic MI, HF, asthma, syncope, and more.PE is a silent killer, and it should be recognized more as a cause of spontaneous cardiac arrest. Where life threatening disease like stroke which is owned by neurological specialists and MI is primarily managed by cardiac specialists, PE is an entity without a professional home. The PERT Consortium brings the specialties together for PE care. 2. Ten years ago, a 58-year-old patient with a large bilateral PE, RV dilation, and positive biomarkers might have been managed with anticoagulation and close observation alone. Today, with evolving—but still uneven—data on advanced therapies, PE care feels far more nuanced and highly dependent on where you practice. What are the major gaps in traditional PE management that clinicians should recognize, and what care pathways should they be aware of across different hospital systems? Care has shifted from anticoagulation‑only to multidisciplinary approaches like catheter directed thrombectomy. Risk‑based pathways and the use of CT angiogram has improved early recognition. Risk stratification tools must be used as tools for early recognition of intermediate risk PE. Untreated PE leads to chronic complications like chronic thromboembolic disease and chronic thromboembolic pulmonary hypertension, which requires long term clinic follow up. 3. What is the role of risk stratification tools such as PeSI, sPeSI scores, cardiac biomarkers, and imaging findings in PE, and how do they guide treatment decisions in real world practice? Integrate vitals (blood pressure and heart rate), biomarkers (troponin, pro-BNP), RV/LV ratio assessment, acid‑base status, and scores. Tools include PESI, sPESI, BOVA, HESTIA, FAST, Geneva, NEWS, shock index. Vitals, lactate, acid-base status, and tools like NEWS or shock index track clinical evolution. PESI/sPESI estimate 30-day mortality and help identify low-risk patients who may be candidates for early discharge or outpatient therapy. Clinical judgment matters—scores don't fully capture clot burden, trajectory, or bleeding risk. 4. How was the pulmonary embolism response team created, and since its creation, what evidence or outcome data became available to support the PERT model? Originated after a sentinel case at MGH: A young, pregnant woman in her 30s, who collapsed at home, underwent thrombectomy, and had to be on ECMO for a few days. The case brought cardiology, cardiac surgeons and critical care physicians together for planning and improvement in her health, which was rewarding. Thereby, it was decided to bring specialties involved in PE care together to create a response team. The name of the team, Pulmonary Embolism Response Team (PERT), was coined by Richard Channick in the first meeting. Posters were set up all over the hospital to call a centralized line when an acute PE is recognized A meeting was held to present the concept of putting together a consortium, with development of action items and a PERT database. Enabled rapid multidisciplinary input using early teleconferencing tools. 5. Given concerns about having too many ‘cooks in the kitchen' during the initial PE call—especially with rotating teams—how can institutions reconcile workflow complexity with standardized pathways in a way that meaningfully supports and justifies the added burden on frontline clinicians? Every hospital's PERT is different, catering to their needs and workflow At least two disciplines are needed to make a PERTData is currently being collected to guide further on how the workflow can be standardized Most importantly, the team brings in resources that were not available prior to PERT formation. 6. What are the main goals of the PERT consortium, and how does it support clinicians and institutions involved? To improve care and improve outcomes for patients with PE Expand education, refine algorithms, standardize care with Centers of Excellence. Maintain the largest PE registry for research and outcomes improvement. 7. Beyond global networking, shared learning from successful systems, and the pathway toward Center of Excellence designation, what additional benefits can clinicians and health systems gain by participating in the PERT Consortium? The ability to learn from other systems, the ability to share experiences. Allow people to develop their professional careers like leadership experience, becoming a member of the trainee council Initiate projects and receive funding for your ideas 8. For trainees interested in pulmonary embolism care, how can a trainee be a champion at their institution? Does PERT provide assistance and how can they really contribute meaningfully even before becoming a fellow/attending? Medical students and residents interested in PE should reach out to the consortium and the consortium will hook you up with the correct mentors who can nurture you along. Listen to the podcasts. Participate with your local PERT team PERT wants involvement of people who are social media savvy to help spread the word on PE. Top three take-away points from this episode Acute PE care has advanced and multiple treatment modalities for acute PE including catheter directed therapy, large bore thrombectomy, are becoming standard of care. Multidisciplinary models like PERT improve coordination and outcomes. Trainees play a vital role in advancing PE care through involvement, research, and education References Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, Huisman MV, Humbert M, Jennings CS, Jiménez D, Kucher N, Lang IM, Lankeit M, Lorusso R, Mazzolai L, Meneveau N, Ní Áinle F, Prandoni P, Pruszczyk P, Righini M, Torbicki A, Van Belle E, Zamorano JL; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020 Jan 21;41(4):543-603. doi: 10.1093/eurheartj/ehz405. PMID: 31504429. https://pubmed.ncbi.nlm.nih.gov/31504429/ Rosovsky R, Zhao K, Sista A, Rivera-Lebron B, Kabrhel C. Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. Res Pract Thromb Haemost. 2019 Jun 9;3(3):315-330. doi: 10.1002/rth2.12216. PMID: 31294318; PMCID: PMC6611377. https://pmc.ncbi.nlm.nih.gov/articles/PMC6611377/ Rosenfield K, Bowers TR, Barnett CF, Davis GA, Giri J, Horowitz JM, Huisman MV, Hunt BJ, Keeling B, Kline JA, Klok FA, Konstantinides SV, Lanno MT, Lookstein R, Moriarty JM, Ní Áinle F, Reed JL, Rosovsky RP, Royce SM, Secemsky EA, Sharp ASP, Sista AK, Smith RE, Wells P, Yang J, Whatley EM; Pulmonary Embolism Research Collaborative (PERC) Attendees. Standardized Data Elements for Patients With Acute Pulmonary Embolism: A Consensus Report From the Pulmonary Embolism Research Collaborative. Circulation. 2024 Oct;150(14):1140-1150. doi: 10.1161/CIRCULATIONAHA.124.067482. Epub 2024 Sep 12. PMID: 39263752; PMCID: PMC11698503. https://pubmed.ncbi.nlm.nih.gov/39263752/ Sharifi M, Awdisho A, Schroeder B, Jiménez J, Iyer P, Bay C. Retrospective comparison of ultrasound facilitated catheter-directed thrombolysis and systemically administered half-dose thrombolysis in treatment of pulmonary embolism. Vasc Med. 2019 Apr;24(2):103-109. doi: 10.1177/1358863X18824159. Epub 2019 Mar 5. PMID: 30834822. https://pubmed.ncbi.nlm.nih.gov/30834822/ Pandya V, Chandra AA, Scotti A, Assafin M, Schenone AL, Latib A, Slipczuk L, Khaliq A. Evolution of Pulmonary Embolism Response Teams in the United States: A Review of the Literature. J Clin Med. 2024 Jul 8;13(13):3984. doi: 10.3390/jcm13133984. PMID: 38999548; PMCID: PMC11242386. https://pubmed.ncbi.nlm.nih.gov/38999548/ Rivera-Lebron B., McDaniel M., Ahrar K., Alrifai A., Dudzinski D.M., Fanola C., Blais D., Janicke D., Melamed R., Mohrien K., et al. Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clin. Appl. Thromb. Hemost. 2019;25:1076029619853037. doi: 10.1177/1076029619853037.https://pubmed.ncbi.nlm.nih.gov/31185730/

durée : 01:06:36 - Club Jazzafip - Le 21 mars, Jazz Magazine investit le Rocher de Palmer pour une rétrospective exceptionnelle : un voyage musical et visuel retraçant plus de 70 ans de passion, porté par les archives iconiques du magazine et une formation d'artistes emmenée par Raphaël Imbert... On en parle au Club ce soir... Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Merci à notre commanditaire ProCafetière : https://tinyurl.com/procafetiere-jerrPour obtenir le Café Whats Up :https://procafetiere.ca/collections/cafe-vrac/products/espresso-whats-up-cafe-vracUtilise le code JERR20 pour 20% de rabais sur le sac Whats Up ;)Pour être l'une des 50 personnes à avoir 1 mois PATREON GRATISSS, Clique icitte :https://www.patreon.com/whatsuppodcast/redeem/9FE48 Étienne-Alexandre Beauregard, jeune intellectuel québécois et figure montante de la nouvelle jeunesse conservatrice, est l'invité de notre podcast. Auteur de Anti-civilisation, il y livre une charge lucide contre les dérives du libéralisme contemporain, explore les impasses de la déconstruction sociale et dénonce la fracture grandissante entre les élites et la volonté des citoyens ordinaires. Une discussion sans détour, qui éclaire les grands bouleversements idéologiques de notre époque et aide à mieux comprendre une partie du monde dans lequel nous vivons. Enregistré le 20 Janvier 2026.Site officiel de Étienne-Alexandre Beauregard :https://eabeauregard.com/FaceBook :https://www.facebook.com/etiennealexandre.beauregard/Son livre Anti-Civilisation :https://www.leslibraires.ca/livres/anti-civilisation-etienne-alexandre-beauregard-9782258211735.htmlPour devenir membre et supporter le Whats Up Podcast : https://www.patreon.com/whatsuppodcast Merci les patreon !!Site web officiel :https://jerrallain.com/Pour suivre Jerr sur Instagram : https://www.instagram.com/jerr_allain/Pour suivre Jerr sur facebook : https://www.facebook.com/JerrAllainofficielContact : jerr.production@gmail.comPour vous abonner à mon Infolettre : http://eepurl.com/hvpnhj

Si la population mondiale devrait continuer d'augmenter au cours des 50 à 60 prochaines années, pour atteindre 10,3 milliards d'habitants, cette croissance est bientôt révolue, selon les prévisions des Nations unies. Au rythme actuel de baisse de la fécondité, nous ne serions plus qu'environ 4 milliards à la fin du siècle. Bien sûr, dans certains pays en Afrique et en Asie notamment le taux de fécondité reste élevé, la dénatalité est devenue un phénomène mondial. Partout autour du globe, en Chine, en Corée du Sud, au Japon, en France, en Italie, on s'inquiète du vieillissement de sa population et de la baisse des naissances. Le spectre de la surpopulation a laissé place à l'angoisse du déclin démographique. Allocations au premier enfant, allongement des congés de naissance, baisse ou gratuité des frais de garde, ... Les pays s'arment de politiques publiques pour tenter d'enrayer la chute de la natalité avec, semble-t-il, des résultats en-deçà de leurs espérances. Ces changements démographiques ne sont pas sans conséquence pour nos sociétés et nos économies, mais sont-elles forcément négatives ? Faut-il chercher à enrayer la baisse de natalité ? Ou repenser l'organisation de sociétés sans enfant ?   Avec : • Pauline Rossi, professeure d'Économie à l'École polytechnique et au Centre de recherche en économie et statistique (CREST). Autrice du livre Le déclin démographique, une urgence économique ? (PUF, 2026) • Jacques Veron, démographe et directeur de recherche à l'Institut national d'Études démographiques (Ined) pour son livre La Démographie de l'extrême (Éditions de La Découverte (2025). Un entretien avec Cléa Broadhust, correspondante de RFI à Pékin en Chine. Après avoir laissé le titre de « pays le plus peuplé » à l'Inde, la Chine voit la baisse de sa population s'accélérer.   Programmation musicale :  ► Dans quelques mois - Orelsan ► Shikishiki - Gazza, Nally.  

Si la population mondiale devrait continuer d'augmenter au cours des 50 à 60 prochaines années, pour atteindre 10,3 milliards d'habitants, cette croissance est bientôt révolue, selon les prévisions des Nations unies. Au rythme actuel de baisse de la fécondité, nous ne serions plus qu'environ 4 milliards à la fin du siècle. Bien sûr, dans certains pays en Afrique et en Asie notamment le taux de fécondité reste élevé, la dénatalité est devenue un phénomène mondial. Partout autour du globe, en Chine, en Corée du Sud, au Japon, en France, en Italie, on s'inquiète du vieillissement de sa population et de la baisse des naissances. Le spectre de la surpopulation a laissé place à l'angoisse du déclin démographique. Allocations au premier enfant, allongement des congés de naissance, baisse ou gratuité des frais de garde, ... Les pays s'arment de politiques publiques pour tenter d'enrayer la chute de la natalité avec, semble-t-il, des résultats en-deçà de leurs espérances. Ces changements démographiques ne sont pas sans conséquence pour nos sociétés et nos économies, mais sont-elles forcément négatives ? Faut-il chercher à enrayer la baisse de natalité ? Ou repenser l'organisation de sociétés sans enfant ?   Avec : • Pauline Rossi, professeure d'Économie à l'École polytechnique et au Centre de recherche en économie et statistique (CREST). Autrice du livre Le déclin démographique, une urgence économique ? (PUF, 2026) • Jacques Veron, démographe et directeur de recherche à l'Institut national d'Études démographiques (Ined) pour son livre La Démographie de l'extrême (Éditions de La Découverte (2025). Un entretien avec Cléa Broadhust, correspondante de RFI à Pékin en Chine. Après avoir laissé le titre de « pays le plus peuplé » à l'Inde, la Chine voit la baisse de sa population s'accélérer.   Programmation musicale :  ► Dans quelques mois - Orelsan ► Shikishiki - Gazza, Nally.  

Le Salon international de l'agriculture se tient jusqu'à ce dimanche 1er mars 2026 à Paris. Cet évènement est considéré comme la vitrine d'un fleuron historique de l'économie française. Mais aujourd'hui, la première puissance agricole de l'Union européenne souffre, au point d'avoir frôlé le déficit commercial l'an dernier (2025). Une situation inédite pour l'ex 2è exportateur mondial. Quels sont les maux qui minent l'agriculture française ? Le modèle doit-il évoluer pour survivre ? Pour en débattre : - Jean-Marie Seronie, agroéconomiste indépendant, membre de l'Académie d'agriculture de France, auteur du livre « 2041, l'odyssée paysanne », aux éditions France Agricole - Ronan Groussier, responsable Agriculture chez Réseau Action Climat - Jean-Baptiste Gibert, agriculteur bio dans le Tarn-et-Garonne, secrétaire général du Syndicat des Jeunes agriculteurs en Occitanie.

Le Salon international de l'agriculture se tient jusqu'à ce dimanche 1er mars 2026 à Paris. Cet évènement est considéré comme la vitrine d'un fleuron historique de l'économie française. Mais aujourd'hui, la première puissance agricole de l'Union européenne souffre, au point d'avoir frôlé le déficit commercial l'an dernier (2025). Une situation inédite pour l'ex 2è exportateur mondial. Quels sont les maux qui minent l'agriculture française ? Le modèle doit-il évoluer pour survivre ? Pour en débattre : - Jean-Marie Seronie, agroéconomiste indépendant, membre de l'Académie d'agriculture de France, auteur du livre « 2041, l'odyssée paysanne », aux éditions France Agricole - Ronan Groussier, responsable Agriculture du Réseau Action Climat - Jean-Baptiste Gibert, agriculteur bio dans le Tarn-et-Garonne, secrétaire général du Syndicat des Jeunes agriculteurs en Occitanie.

Denis Riché est nutritionniste, spécialiste en micronutrition et cofondateur du magazine Sport & Vie. Son dernier livre Epinutrition: Comment notre assiette et notre environnement modifient nos gènes est disponible partout.Site internet : ⁠https://denisriche.ch/⁠Instagram : ⁠https://www.instagram.com/denisriche3/⁠Livre Amazon : ⁠https://amzn.to/4094Kb3⁠ CHAPITRES :0:00 Introduction1:06 Déclin cognitif : mythe ou réalité ?5:13 Facteurs environnementaux et évolution cognitive10:45 Nutrition et santé cérébrale18:35 Alzheimer et déclin cognitif22:36 Émotions et intelligence humaine24:43 Résilience et éducation27:24 Équilibre entre stress et alimentation33:47 Besoins nutritionnels et choix alimentaires45:11 Tabac, alcool et santé cognitive49:59 Hormèse et consommation modérée53:09 Hygiène de sommeil et choix de vie58:10 Impact du sucre sur le cerveau1:03:40 Insuline et santé cognitive1:07:42 Nutrition et carences1:10:34 Importance des oméga-31:26:28 Rôle des protéines dans la cognition1:31:34 Complexité de la nutrition1:37:42 Café et cognition1:40:27 Détox et nutrition1:42:11 Nutriments essentiels pour le cerveau BIOMÉCANIQUE :​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Discord⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠​⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠La Lettre Biomécanique⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠™⁠⁠ Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Stress fractures are common injuries in athletes and military recruits, that's' understandable- based on the physical forces placed on the long bones. A stress fracture can be defined as a partial or complete fracture of the bone that is a result from repeated application of stress lower than that required to fracture the bone in a single loading situation. In pregnancy, the body is subjected to various physiological changes that make women more vulnerable. In this pregnancy, we will highlight a REAL patient case which our team cared for on the inpatient service where a simple cough at 34 weeks leads to a painful spontaneous rib fracture! Is there any data published on this? Are serum tests for bone turn-over required as part of this workup? Listen in for clinical pearls!1. 1962: Long A.E.: “Stress fracture of the ribs associated with pregnancy”. Surg. Clin. North Am., 1962, 42, 909.2. 2000: Baitner AC, Bernstein AD, Jazrawi AJ, Della Valle CJ, Jazrawi LM. Spontaneous rib fracture during pregnancy. A case report and review of the literature. Bull Hosp Jt Dis. 2000;59(3):163-5. PMID: 11126720. https://pubmed.ncbi.nlm.nih.gov/11126720/3. 2015: Rib stress fractures in pregnancy: a case report and review of literature. chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/file:///C:/Users/hchapa/Downloads/1575956493464-5157163%20(1).pdf4. Zhang Y, Li R, Zhang J, Zhou W, Yu F. Changes in Serum Concentrations of Bone Turnover Markers in Healthy Pregnant Women. International Journal of Clinical Practice. 2023.

Aujourd'hui, Didier Giraud, éleveur de bovins, Barbara Lefebvre, prof d'histo-géo, et Charles Consigny, avocat, débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

It's a controversial topic: the impact of uterine incision (hysterectomy) on the neonate delivery interval (also called the U-D interval). Does it matter? Just to be clear, we're talking about time from uterine entry to fetal extraction, not skin incision to fetal extraction. Past publications have produced conflicting results, often limited by small sample sizes, heterogeneous indications for delivery, and reliance on surrogate markers (like apgar scores) rather than clinical morbidity. But a new study published in the Gray journal at the end of 2025 (December 30, 2025) gives some new insights. In this episode, we will review this retrospective study and play the “Devil's advocate” as we summarize the rebuttal data. As the reports are conflicting, we will end the podcast with a real-world interpretation and application of this data. Listen in for details. 1. Bart, Yossi et al. Uterine Incision-to-Delivery Interval and Neonatal Outcomes among Non-urgent, Term, Cesarean Deliveries. American Journal of Obstetrics & Gynecology, Volume 0, Issue 0. https://www.ajog.org/article/S0002-9378(25)00980-9/fulltext?rss=yes2. Maayan-Metzger A, Schushan-Eisen I, Todris L, Etchin A, Kuint J. The effect of time intervals on neonatal outcome in elective cesarean delivery at term under regional anesthesia. Int J Gynaecol Obstet. 2010 Dec;111(3):224-8. doi: 10.1016/j.ijgo.2010.07.022. Epub 2010 Sep 19. PMID: 20855070. https://pubmed.ncbi.nlm.nih.gov/20855070/3. Spain JE, Tuuli M, Stout MJ, Roehl KA, Odibo AO, Macones GA, Cahill AG. Time from uterine incision to delivery and hypoxic neonatal outcomes. Am J Perinatol. 2015 Apr;32(5):497-502. doi: 10.1055/s-0034-1396696. Epub 2014 Dec 24. PMID: 25539409.4. Bader AM, Datta S, Arthur GR, Benvenuti E, Courtney M, Hauch M. Maternal and fetal catecholamines and uterine incision-to-delivery interval during elective cesarean. Obstet Gynecol. 1990 Apr;75(4):600-3. PMID: 2107478.5. Tekin, E., Inal, H.A. & Isenlik, B.S. A Comparison of the Effect of Time from Uterine Incision to Delivery on Neonatal Outcomes in Women with One Previous and Repeat (Two or More) Cesarean Sections. SN Compr. Clin. Med. 5, 80 (2023). https://doi.org/10.1007/s42399-023-01427-x

Dans cet épisode du podcast La Pause Fitness nous allons parler de déclin physique, perte de poids et mythes métaboliques. NOUVEAU : La Flexibilité Métabolique : Le vrai secret de la performance (et comment la mesurer) Au programme : Déclin physique : une étude suédoise de 47 ans identifie 35 ans comme l'âge charnière Des […] The post Passé 35 ans, tout change : Êtes-vous déjà en déclin physique ? appeared first on Fitnessmith.